To test this hypothesis, we combined the NNMT inhibitor NNMTi23 with the glucose analogue 2‐DG, a potent inhibitor of glycolysis, or BPTES, an inhibitor of GLS, and monitored cell viability of 786‐O and A498 cell lines, and primary ccRCC models (RCC1 and RCC2). This evidence concerns the gene GLS and nonpapillary renal cell carcinoma.